Background: Discrepant and often contradictory results have accumulated regarding the antidepressant and procognitive effects of serotonin transporter (SERT) antagonists in Alzheimer's disease.
Background
The discussion surrounding the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in Alzheimer's disease (AD) and related dementias has extended beyond the drugs' effects on comorbid depression [1] . Clinical studies on the incidence of dementia have reported an increased risk of cognitive impairment following SSRI treatment [2] , but also beneficial delays in the conversion from mild cognitive impairment to AD [3] . In preclinical studies, the chronic administration of SSRIs to transgenic models of AD may improve cognitive performance [4, 5] , but also increases mortality rates compared to vehicle administration [6, 7] . The reasons for the heterogeneity in the antidepressant and cognitive effects of SSRIs in AD remain unknown.
The serotonin transporter (SERT) is the primary target of SSRI treatment [8] . By blocking SERT, SSRIs inhibit the clearance of extracellular serotonin (5-HT) and potentiate serotonergic neurotransmission. There is evidence to suggest that the brain levels of SERT change dynamically with AD progression. The binding of [ 3 H]escitalopram is higher than control levels in the cortex and hippocampus of 4-month-old APP swe /PS1 dE9 mice [9] , a model of familial AD harboring mutations in the amyloid precursor protein (APP) and presenilin-1 (PSEN1; PS1) genes [10] . In the hippocampus of 3xTg-AD mice, a model of combined amyloidosis and tauopathy, elevated SERT immunoreactivity has been observed by 3 months of age, i.e., prior to the manifestation of amyloid-β (Aβ)-induced memory impairment or the deposition of plaques [11, 12] . These "early" increases in the density of SERT, which may decrease the level of extracellular 5-HT, contrast the degenerative reductions in the levels of several serotonergic components, including SERT, which are typically observed in the brain of aged amyloidosis models [13, 14] and advanced cases of AD [15] . The aforementioned literature implies that a low serotonergic tone may be associated with both increased and decreased SERT-binding levels, according to disease stage. Thus, it is plausible that the therapeutic efficacy of SSRIs will vary considerably during the course of AD, depending on the density and/or activity of the SERT.
Chronic, low-grade neuroinflammation constitutes hallmark AD pathology [16] . Neuroinflammation has been demonstrated in the brain of living demented patients and models of AD by molecular imaging of the translocator protein (TSPO), which is primarily a marker of microgliosis [17] . The neuroinflammatory reaction is characterized by increased microglial production of inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor [TNF [18, 19] ]. Moreover, IL-1β, TNF, and interleukin-6 (IL-6) are elevated in the periphery of AD patients compared to non-AD subjects [20] . Interestingly, these pro-inflammatory cytokines have been reported to alter SERT function in a cytokine-specific manner. In the mouse midbrain and striatum, IL-1β can stimulate SERT activity, by decreasing the apparent Michaelis constant (K m ) of the transporter for 5-HT [21] . In neuronal cell lines and mouse synaptosomal preparations, TNF decreases K m and increases the apparent maximal velocity rate (V max ) of 5-HT uptake [22] . Unlike the stimulating effects of IL-1β and TNF, treatment with IL-6 reduces the mRNA and protein levels of SERT in the mouse hippocampus [23] . These data are indicative of a cytokine-induced mechanism for the dysregulation of SERT, which could interfere with serotonergic neurotransmission during the course of AD.
In the present study, SERT density and function were evaluated in parallel with markers of neuroinflammation in the brain of aging APP swe /PS1 dE9 mice. It was hypothesized that the progression of amyloidosis would be associated with age-related alterations in the binding levels of SERT, which could be attributed to increased levels of specific neuroinflammatory markers.
Materials and methods

Animals
A total of 113 APP swe /PS1 dE9 transgenic (TG) and littermate wild-type (WT) control mice were used in this study (109 females; 4 males). The animals were bred and maintained on a C57BL/6J background in the Biomedical Laboratory of the University of Southern Denmark. Mice were group-housed in a temperature (21 ± 1°C) and humidity (45-65%) controlled environment, under a 12/12-h light/dark cycle (lights on: 7 am), with free access to food and water. Animals were euthanized by cervical dislocation at 3, 6, 12, 18, and 24 months of age (n = 6/group, total number = 60). The brains were immediately removed, placed on a petri dish containing ice, and bisected along the midline. The brainstem from the left hemisphere was frozen on dry ice and used for measuring Scl6a4 (Sert) mRNA levels by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR). The right brain hemisphere was immersed for 2 min in isopentane on dry ice (− 30°C) and used for autoradiography. Consecutive, 20-μm-thick sagittal sections were collected on ice-cold SUPERFROST™ slides at 300 μm intervals, by using a Leica CM3050S cryostat (Nussloch, Germany). The sections were dried overnight at 4°C in a box containing silica gel and stored at − 80°C until use.
[ 3 H]DASB autoradiography was used to measure the density of SERT, as described previously [24] . Sections were thawed at room temperature (RT) and prewashed in 50-mM Tris-HCl buffer (pH 7.4), containing 150 mM NaCl and 5 mM KCl (3 × 15 min). The sections were subsequently incubated for 2 h in the same buffer, containing 1 nM [ 3 H]DASB (specific activity 80 Ci/mmol; ART1523, American Radiolabeled Chemicals, Inc.). To determine non-specific binding (NSB), adjacent sections were radiolabeled with 1 nM [
3 H]DASB in the presence of 10 μM paroxetine HCl hemihydrate (P9623; SigmaAldrich). Incubations were terminated by three 1-min washes into ice-cold 50-mM Tris-HCL buffer (pH 7.4), followed by a rapid rinse in ice-cold deionized H 2 O (dH 2 O, Ultra-Clear; Siemens).
[ 3 H]PK11195 autoradiography was used to measure the density of the neuroinflammatory marker TSPO [25] . Sections were thawed at RT and prewashed in 50-mM Tris-HCl buffer (pH 7.4), containing 150 mM NaCl, 5 mM KCl, 1.5 mM MgCl 2 , and 1.5 mM CaCl 2 . Incubations were carried out for 2 h in the same buffer, containing 3 nM [ 3 H]PK11195 (specific activity 82.7 Ci/ mmol; NET885, PerkinElmer). NSB was determined in the presence of 10 μM unlabeled PK11195 (C0424; Sigma-Aldrich). The incubations were terminated as described for [ 3 H]DASB. The labeled sections were dried for 2 h under a stream of cold air and placed against Carestream® Kodak® BioMax MR film for a period of 25 days. To allow quantification, 3 H microscales of known radioactive concentration were also apposed to each film (American Radiolabeled Chemicals, Inc.). After development with KODAK substitute D-19 developer (TED PELLA, Inc.), images were digitized using a white sample tray and the Coomassie Blue settings on a ChemiDoc™ MP imaging system (BIO-RAD). Values of specific binding were calculated by subtracting the level of non-specific from total binding levels, using ImageJ software (v1.50e; National Institutes of Health, MD, USA). For each animal, specific binding in the frontal, parietal, occipital, and temporal cortices was analyzed on 2-6 consecutive sections, by reference to the Allen Mouse Brain Atlas for sagittal sections [26] .
Sert RT-qPCR
Trizol®-isolated RNA (2 μg) from the brainstem of 3-, 6-, 12-, 18-, and 24-month-old TG and WT mice was reverse-transcribed to cDNA with the Applied Biosystems™ high-capacity cDNA transcription kit (Thermo Fisher Scientific). Samples of 20 μL were run in triplicate on a StepOne-Plus™ Real-Time PCR system (Applied Biosystems™, Thermo Fisher Scientific). Each sample contained nuclease-free H 2 O (Thermo Fisher Scientific), 1× Maxima SYBR green/probe master mix (Thermo Fisher Scientific), 500 nM forward and reverse primers (TAG Copenhagen A/S), 5× diluted cDNA for Sert, and 10× diluted cDNA for hypoxanthine phosphoribosyltransferase (Hprt), which was used as a reference gene. Primer sequences for Hprt and Sert have been described previously [24, 27] . After normalization to Hprt, data were expressed as fold-change from the mean Sert/Hprt ratio of 3-month-old WT mice. Nuclease-free H 2 O and genomic DNA instead of cDNA were used to control for contamination.
[ 3 H]5-HT transport assay
The assay was performed as detailed previously [22] , using freshly isolated cortical tissue from a female, 3-, 6-, 12-, and 20-month-old, WT and TG mice (n = 5-7/group, total number = 49). Freshly prepared homogenates were required for the assay, as preparations of frozen material led to undetectable levels of specific binding.
Cortices were homogenized in 10 vol (w/v) of ice-cold HEPES (10 mM)/sucrose (0.32 M) buffer (pH 7.4), by using a motor-driven, Teflon-glass tissue grinder at 800 rpm (Wheaton Instruments). The homogenate was centrifuged for 10 min at 1000×g in a refrigerated centrifuge (4°C; RC M150 GX, Sorvall). The pellet was discarded, and 200 μL of the supernatant (S1) kept on ice for determining the levels of IL-1β, IL-6, TNF, and Aβ 40/42 by Meso Scale Discovery immunoassays. The S1 supernatant was transferred to clean tubes and centrifuged at 100,000×g for 20 min (4°C). The resulting pellet was suspended in 10 mM HEPES buffer (pH 7.4), containing 130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 1.8 g/l glucose, 100 mM pargyline, and 100 mM L-ascorbic acid (assay buffer). Total protein concentration was determined with a Pierce™ BCA protein kit (Thermo Fisher Scientific).
The membrane suspension was pre-incubated for 10 min at 37°C in a BINDER shaking incubator (BFD53; VWR). Incubations were carried out for 5 min at 37°C, using six concentrations of 1.0 Ci/mmol [ 3 H]5-HT (20 nM -2.5 μM), which was prepared by diluting the specific activity of stock [
3 H]5-HT (76.3 Ci/mmol; NET1167, PekinElmer) with unlabeled 5-HT (#14927; Sigma-Aldrich). The final assay volume was 200 μL, composed of 160 μL freshly prepared membrane suspension, 20 μL assay buffer, and 20 μL of [ 3 H]5-HT in assay buffer. Specific uptake was defined as total uptake minus uptake in the presence of 10 μM paroxetine HCl hemihydrate. Under these conditions, maximally observed radioligand depletion was 14% at 20 nM [
3 H]5-HT. The reactions were stopped by vacuum filtration through Whatman GF/B filters, pre-soaked for 1 h in 0.1% polyethylenimine. The filters were washed three times with 3 mL of ice-cold assay buffer (pH 7.4), all procedures carried out using a 48-well Brandel harvester. Filter disks were placed in 5 mL scintillation liquid (Optiphase Hisafe 3; PerkinElmer) and shaken vigorously. Following overnight equilibration, bound radioactivity was measured in a Tricarb 2910 TR liquid scintillation counter (PerkinElmer) for 5 min/sample.
To determine the effects of Aβ on the kinetics of [ 3 H]5-HT transport, membranes isolated from the forebrain of 3-month-old wild-type animals (n = 4) were incubated with increasing concentrations of [ 3 H]5-HT as described above, in the presence or absence of 100 nM lyophilized trifluoroacetate salts of synthetic human Aβ 40 (#03138; Invitrogen) and Aβ 42 (#03112; Invitrogen). These peptide concentrations were based on the levels of soluble Aβ measured in the S1 supernatant from the brain of 20-month-old APP swe /PS1 dE9 mice by Meso Scale Discovery. Aβ was dissolved in assay buffer and added to the incubation mixture immediately before the 10-min pre-incubation period of the membrane suspension. 
Meso Scale Discovery analysis of IL-1β, IL-6, TNF, and Aβ
The concentration of IL-1β, IL-6, and TNF in the S1 supernatant from the cortices of 3-, 6-, 12-, and 20-month-old WT and TG mice was determined with a custom-designed V-PLEX mouse pro-inflammatory kit, according to manufacturer instructions (K152AOH-2; Meso Scale Diagnostics, LLC). Levels of soluble Aβ 42 and Aβ 40 in the S1 supernatant were measured with the V-PLEX Aβ peptide kit (K15200E-2; Meso Scale Diagnostics, LLC). Plates were processed in a SECTOR® Imager 6000 plate reader (Meso Scale Diagnostics, LLC), and data acquired with Discovery Workbench software (v4.0; Meso Scale Diagnostics, LLC). Results are presented as pg of protein/mg of total protein, the latter determined with a Pierce™ BCA protein kit, and bovine serum albumin as standard (Thermo Fisher Scientific). 40/42 were derived from 3 independent experiments and compared by two-tailed independent t tests. A two-way ANOVA, followed by Bonferroni posttests, was used to examine the effects of age and genotype on the levels of Sert, TNF, IL-1β, IL-6, Aβ 40 , and Aβ 42 . Throughout all experiments, samples from APP swe /PS1 dE9 TG and WT control groups were processed in parallel. Significance was set at α ≤ 0.05, and the ANOVAs performed using Statistica™ software (v10; TIBCO Software, Inc.). Values are presented as the mean ± standard error of the mean (SEM) of n replicates/experiment.
Experimental design and statistical analysis
Results
SERT density is decreased in the neocortex of aging APP swe /PS1 dE9 mice (Fig. 2) . PCR products of 5× diluted Sert cDNA were determined after 24 cycles. A single peak at 81°C was obtained by melt-curve analysis, and no signal detected in the genomic DNA and . By one-way ANOVA, the V max /K m ratio decreased in an age-dependent manner in APP swe / PS1 dE9 mice [F (3, 10) = 3.9, p = 0.045]. However, the reduction was small, and individual Bonferroni comparisons did not reveal significant differences in SERT's efficiency between groups of aging TG mice (p > 0.05).
The effects of soluble Aβ 40 and Aβ 42 (100 nM) on the baseline transport of [ 3 H]5-HT were examined in membranes isolated from the forebrain of 3-month-old WT mice (Fig. 3a) . Aβ 40 (Fig. 4a) . Representative autoradiograms are presented in Fig. 4b .
There were increased TSPO-binding levels in the neocortex of APP swe /PS1 dE9 TG vs. WT control animals Values are reported as the mean ± SEM of 3-4 independent experiments, conducted on freshly prepared membranes from the neocortex of aging wild-type (WT) and APP swe /PS1 dE9 littermate transgenic (TG) mice. The apparent maximal velocity rate (V max ) for the uptake of [ Age-dependent changes in the binding levels of [ 3 H]PK11195 were inversely correlated with [ 3 H]DASB--binding levels in the parietal, but not the frontal, occipital, and temporal cortices of APP swe /PS1 dE9 TG mice (Fig. 5) .
Increased levels of IL-1β, IL-6, and TNF in the neocortex of aging APP swe /PS1 dE9 and WT control mice
The concentration of IL-1β, IL-6, and TNF was measured in the S1 supernatant fraction from the neocortex of 3-, 6-, 12-, and 20-month-old WT and TG animals ( Table 2) .
Levels of IL-6 were increased in 20 vs. Age-related changes in the ratio of soluble Aβ 40 /Aβ 42 in the neocortex of APP swe /PS1 dE9 mice Levels of Aβ 40 and Aβ 42 were measured in the S1 supernatant fraction from 3-, 6-, 12-, and 20-month-old WT and TG animals ( Table 3 ). There were significant main effects of age [F (3, 51) = 13.5, p = 0.000] and genotype [F (1, 51) = 30.4, p = 0.000], as well as significant age × genotype interaction effects on the levels of soluble Aβ 40 [F (3, 51) = 13.6, p = 0.000], which were increased in the cortex of 
Discussion
In the present work, age-dependent changes in the density and function of the SERT were assessed in parallel with markers of neuroinflammation in the neocortex of APP swe /PS1 dE9 mice. Increased levels of the neuroinflammatory markers TPSO and IL-1β preceded reductions in the density and activity of the SERT, which were observed in aged, 18-24-month-old TG animals. There was no indication of direct, cytokine-induced alterations in the binding levels of SERT, at any of the time-points examined. However, there was an Aβ 40 -induced reduction in the rate of [ 3 H]5-HT uptake, indicating that SERT activity, and the effects of SERT antagonism, may depend on amyloid status. The concentration of IL-1β, IL-6, and TNF was measured in the S1 supernatant fraction from neocortical homogenates of aging wild-type (WT) and APP swe /PS1 dE9 transgenic (TG) mice, by using Meso Scale Discovery. Genotype-induced effects on cytokine levels were solely observed for IL-1β, which was increased over agematched control values at the 12-month time-point. The concentration of all pro-inflammatory cytokines increased with age, in both TG and WT animals. Values of IL-1β, IL-6, and TNF were normalized to total protein content and reported as the mean ± SEM of 3-4 independent experiments. SERT density is considered to be a representative marker of the integrity of the serotonergic afferents, given that the transporter is primarily located on serotonergic nerve terminals and axons in the adult brain [28] . In humans, postmortem SERT autoradiography [29, 30] , as well as neuroimaging studies with the SERT-selective tracer [ 11 C] DASB [31, 32] , has reported reduced SERT availability in the neocortex of AD patients, compared to non-demented subjects. In keeping with this literature, the binding of [ 3 H]DASB decreased in the frontal and parietal cortex of 18-24-month-old APP swe /PS1 dE9 mice, a reduction that is likely associated with degenerative changes in the serotonergic terminals of aged TG animals. Supporting this suggestion, Sert mRNA levels were not different between TG and WT mice, indicating that the decreased binding of [ 3 H]DASB is not due to decreased Sert expression, at least when the entire raphe nuclei are assayed by RT-qPCR [24] . These findings are consistent with reports that the density of serotonergic axons is reduced by~50% in the neocortex of 18-month-old APP swe /PS1 dE9 mice, as evidenced by stereological analysis of 5-HT immunostained fibers [14] . The decrease in [ 3 H]DASB binding further ties in with the reduction in the V max of [ 3 H]5-HT uptake in 20-month-old TG vs. WT animals, since the velocity of substrate uptake depends on the concentration of transporter protein according to Michaelis-Menten kinetics. In terms of the therapeutic efficacy of SSRIs in AD, these results suggest that the effects of SERT antagonism may decline at the advanced stages of amyloidosis, in accordance with the reduction in the availability of SERT.
In addition to potential disruptions in cortical serotonergic innervation, the addition of Aβ 40 in membrane preparations from WT animals reduced the V max of [ 3 H]5-HT uptake from its control value by~20%. The magnitude of decrease is within the range reported by studies assaying SERT activity in biopsy specimens from the neocortex of AD patients [33, 34] 40 , an observation on the regulation of soluble Aβ that we have previously reported in aging APP swe /PS1 dE9 mice [18] .
Acute SSRI treatment has been shown to immediately reduce the levels of Aβ 40/42 in the brain interstitial fluid of APP swe /PS1 dE9 mice [35] , as well as in the cerebrospinal fluid of healthy human volunteers [36] , supporting a direct association between SERT function and amyloidosis. However, the Aβ-lowering effects of SSRIs have not been reported consistently in humans [37] , nor in APP swe /PS1 dE9 mice [38] . Studies on the kinetics of [ 3 H]5-HT uptake in platelets from AD patients have also been inconsistent, reporting decreased V max and K m [39] , decreased V max and unaltered K m [40] , and cognitive-status-dependent changes in the V max of [ 3 H]5-HT in demented vs. non-demented subjects [41] . The observation that Aβ 40 reduces the baseline uptake rate of [ 3 H]5-HT could explain the discrepant findings, since it demonstrates that the activity of SERT is specifically dependent on the levels of Aβ 40 .
Although TNF, IL-1β, and IL-6 have been shown to regulate the density and function of the SERT, there was no evidence of a direct, cytokine-mediated mechanism for the decreased SERT-binding levels in the current study. The concentration of IL-6, which has been reported to reduce [ 3 H]5-HT uptake, SERT mRNA, and SERT protein levels [23] , was age-dependently increased in both APP swe /PS1 dE9 and WT animals. Similarly, there 
